A Phase II Randomised, Double-blind, Placebo-controlled Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 mircog, 2.5 microg and 5 microg) Delivered Via Respimat Inhaler Once Daily in the Evening in Children 6 to 11 Yrs Old With Moderate Persistent Asthma.

Trial Profile

A Phase II Randomised, Double-blind, Placebo-controlled Incomplete Crossover Trial With 4-week Treatment Periods to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (Doses of 1.25 mircog, 2.5 microg and 5 microg) Delivered Via Respimat Inhaler Once Daily in the Evening in Children 6 to 11 Yrs Old With Moderate Persistent Asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2016

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 18 May 2016 Results of five trials (n=1397) presented at the 112th International Conference of the American Thoracic Society
    • 20 Oct 2012 Planned number of patients changed from 101 to 104.
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top